Summit Therapeutics Inc.: Leerink Partners raises target price to $13 from $11
SMMT•Leerink Partners raised its target price for Summit Therapeutics to $13 from $11.
Related News
uniQure says AMT-130 data show 80% slowing on cUHDRS at 36 months in high-dose patients
QURE•
Valvoline lifts share repurchase authorization by $175 million to $500 million remaining
VVV•
China expects strongest super El Nino event on record this year
SPY•
One and One Green Technologies net income rises 17% to $4.49 million as revenue climbs 19%
YDDL•
Can the AI boom fix the US budget problem?
SPY•